Figure 2.

The COVID-19 pandemic impact on the use of surgery after chemotherapy initiation by cancer type. Legend: We report the subdistribution hazard ratios (sHRs) and associated 95% confidence intervals of receiving surgery within 9 months after chemotherapy initiation in the pandemic relative to pre-pandemic period for each cancer type. sHRs were computed from a multivariable Fine-Gray regression model, where interaction of the COVID-19 pandemic indicator (pandemic vs. pre-pandemic) with cancer type was included. “Other” includes central nervous system, cervical, endocrine, genitourinary, head and neck, and other cancer types with unknown or ill-defined primary site. sHRs that are significantly different from 1 were highlighted in black, while insignificant sHRs were plotted in gray. A sHR > 1 implies an increased use of surgery within 9-month following chemotherapy initiation in the pandemic relative to pre-pandemic period.